Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Rankning i aktier #36446
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aktiekurs
$1.73
Senast synkroniserad: 2025-06-17
Marknadsvärde
$2.55M
Förändring (1 dag)
-0.29%
Förändring (1 år)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)

Kategori

Healthcare
Historik för aktiesplit för Eiger BioPharmaceuticals, Inc. (EIGR)
Aktien Eiger BioPharmaceuticals, Inc. (symbol: EIGR) har genomgått totalt 2 aktiesplitar.
Den senaste spliten skedde den Jan 08, 2024.
En EIGR-aktie köpt före Mar 23, 2016 motsvarar nu 0.0022222222222222 EIGR-aktier.
Lista över aktiesplitar
År Split Multipel Kumulativ multipel
2024-01-08 1:30 x0.033333333333333 x0.0022222222222222
2016-03-23 1:15 x0.066666666666667 x0.066666666666667
Aktiesplitar för liknande företag eller konkurrenter
Företag Antal aktiesplitar Kumulativ multipel Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL